Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review (Q34629029)

3 August 2017

1 reference

title

Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review (English)

1 reference

3 August 2017

0 references

1 reference

1 reference

1 reference

1 reference

Diane L Lorenzetti

2

0 references

Roger E. Thomas

series ordinal

1

object named as

Roger E Thomas

1 reference

3 August 2017

Wendy Spragins

3

1 reference

3 August 2017

Dave Jackson

series ordinal

4

1 reference

3 August 2017

Tyler Williamson

series ordinal

5

1 reference

3 August 2017

language of work or name

English

0 references

publication date

5 May 2011

1 reference

3 August 2017

12

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

3 August 2017

29

1 reference

3 August 2017

28

1 reference

3 August 2017

4544-4555

1 reference

17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Immune response during adverse events after 17D-derived yellow fever vaccination in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Short report: Incidence of yellow fever vaccine-associated neurotropic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Anaphylaxis from yellow fever vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Adverse event reports following yellow fever vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Risk of fatal adverse events associated with 17DD yellow fever vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Viscerotropic disease following yellow fever vaccination in Peru

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Standardized case definitions of adverse events following immunization (AEFI)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Yellow fever vaccination and pregnancy: a four-year prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Combined vaccination against yellow fever and typhoid fever: a comparative trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Early exposure to yellow fever vaccine during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Vaccination by scarification with a combined 17D yellow fever and vaccinia vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Comparison of the immunogenicity and safety of two 17D yellow fever vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Study of combined vaccination against yellow fever and measles in infants from six to nine months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Yellow fever 17D vaccine safety and immunogenicity in the elderly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

A clinical study of stabilized 17D strain live attenuated yellow fever vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Comparative clinical study of a new 17D thermostable yellow fever vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Effect of interval between inoculation of live smallpox and yellow-fever vaccines on antigenicity in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Surveillance system of vaccine adverse events and local data analysis--the experience in a middle-sized city in Brazil, 1999-2001.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Advanced Age a Risk Factor for Illness Temporally Associated with Yellow Fever Vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Yellow Fever Vaccine Post-marketing Surveillance in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Surveillance for adverse events following immunization (AEFI) in Switzerland--1991-2001.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Guillain-Barre syndrome after vaccination in United States a report from the CDC/FDA Vaccine Adverse Event Reporting System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Evaluation of thermostable yellow fever vaccine from the Pasteur Institute on international travellers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Encephalitis in an infant after vaccination with 17 D yellow fever virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Impact of vaccines given during pregnancy on the offspring of women consulting a travel clinic: a longitudinal study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Yellow fever vaccination during pregnancy and spontaneous abortion: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Exposure to yellow fever vaccine in early pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Congenital yellow fever virus infection after immunization in pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Vaccination in Brazilian HIV-infected adults: a cross-sectional study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Yellow fever vaccine is safe and effective in HIV-infected patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.055

10.1016/J.VACCINE.2011.04.055

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference